Please login to the form below

Not currently logged in
Email:
Password:

ELND005

This page shows the latest ELND005 news and features for those working in and with pharma, biotech and healthcare.

Transition takes on Lilly muscle-boosting drug

Transition takes on Lilly muscle-boosting drug

Meanwhile, the Canadian company also has an in-house candidate - ELND005 - for the treatment of agitation and aggression in Alzheimer's disease as well as neuropsychiatric symptoms in Down's syndrome

Latest news

  • FDA fast-tracks Elan’s Alzheimer’s drug FDA fast-tracks Elan’s Alzheimer’s drug

    FDA fast-tracks Elan’ s Alzheimer’ s drug. Speeds up regulatory process for ELND005 for the treatment of neuropsychiatric symptoms. ... Elan's limited pipeline received a boost yesterday with the decision by the US Food and Drug Administration (FDA)

  • Royalty Pharma raises Elan bid as deals keep coming Royalty Pharma raises Elan bid as deals keep coming

    Finally, Speranza is a new company set up in Ireland to handle the development of ELND005 (scyllo-inositol), a clinical-stage drug candidate with potential in bipolar disease, agitation and aggression

  • Elan spins out research business

    Elan will be left with a business focusing mainly on Tysabri (natalizumab) for multiple sclerosis, partnered with Biogen, as well as pipeline drugs ELND005 for central nervous system disorders and its

  • Pfizer and Medivation part company after Alzheimer's trial failure

    The drug follows late-stage failures for several other disease-modifying Alzheimer's candidates, including Eli Lilly's semagacestat and Elan's ELND005.

  • Lifting the fog

    Other late-stage failures. Another drug that is close to treading the same path as semagacestat is ELND005 (Elan). ... In a phase II trial, low-dose ELND005 failed to outperform placebo in primary cognitive and functional endpoints.

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Pharma deals during June 2013 Pharma deals during June 2013

    elected not to close the various deals on offer as noted in aie the Theravance, AOP Orphan and the Speranza ELND005 transactions.

  • Pharma deals during May 2013 Pharma deals during May 2013

    And thirdly, an unusual deal where Elan spins out its clinical stage CNS asset ELND005 to a new company, Speranza, whereby Elan pays Speranza (not the other way around) up to ... senior management who work on ELND005 and who will transfer from Elan to

  • Deal Watch table for May 2013 Deal Watch table for May 2013

    Elan/ Speranza. Product spin out. Product spin out ELND005 phase 2 CNS drug.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics